Thermo Fisher Scientific Inc. (NYSE:TMO) on Thursday reported first-quarter 2026 adjusted earnings of $5.44 per share, beating the street view of $5.24.
The life science giant’s quarterly sales of $11.01 billion increased 6% year-over-year, beating the analyst consensus estimate of $10.85 billion. Organic revenue growth was 1%.
Segment Performance Shows Strength In Bioproduction
Life Sciences Solutions sales increased 12.6% to $2.64 billion. Analytical Instruments sales were flat at $1.72 billion.
data-variant=”card”
data-news-mode=”manual”
>
Read Also:
Seer Joins Thermo Fisher Tools In Large-Scale Proteomics Effort